Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428888 | 0.89 | HPGD (0.47) | CPS1HPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1136220 | 0.81 | HTR1A (0.39) | HPGDALDH1A1KDM4EHSD17B10TDP1 | |
| SCHEMBL1136218 | 0.78 | EGFR (0.44) | HPGDALDH1A1KDM4EHSD17B10RAB9A | |
| SCHEMBL1136187 | 0.77 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10RAB9AGSK3B | |
| SCHEMBL1136181 | 0.76 | IDO1 (0.40) | HPGDALDH1A1KDM4EHSD17B10RAB9A | |
| SCHEMBL1136064 | 0.74 | KDM1A (0.42) | HPGDALDH1A1KDM4EGSK3BTDP1 | |
| SCHEMBL1136323 | 0.74 | HPGD (0.48) | HPGDALDH1A1KDM4EHSD17B10GSK3A | |
| SCHEMBL2493104 | 0.73 | MET (0.41) | ALDH1A1KDM4EHSD17B10RAB9AGSK3B | |
| SCHEMBL2584922 | 0.73 | PTGDR2 (0.50) | ALDH1A1KDM4EPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL1136283 | 0.73 | KDR (0.38) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-9403773-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | US | disclosed |
| US-9045464-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642619-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-8269011-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-2152699-B1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CPS1 4086/4885HPGD 493/4885ALDH1A1 692/4885 |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CPS1 4086/4885HPGD 493/4885ALDH1A1 692/4885 |
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CPS1 4086/4885HPGD 493/4885ALDH1A1 692/4885 |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CPS1 4086/4885HPGD 493/4885ALDH1A1 692/4885 |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | CPS1 4086/4885HPGD 493/4885ALDH1A1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.